GlassScriptPhysician profile
Lewis I Apter
NPI 1649215369
$2,513.18
in general payments reported to CMS, 2019-2025
23 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $176 · 2021: $164 · 2022: $234 · 2023: $393 · 2024: $231 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $281.14 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $264.21 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $239.99 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $204.80 | 2019-2024 | Eylea, Eylea Hd |
| Sun Pharmaceutical Industries INC. | $162.91 | 2019-2025 | |
| Abbvie INC. | $149.88 | 2023 | Vuity, Alphagan P, Lumigan |
| Aerie Pharmaceuticals, INC. | $147.06 | 2019 | |
| Alcon Vision LLC | $143.48 | 2019-2024 | Rocklatan |
| Dompe US, INC. | $120.97 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.22 | 2019-2021 | |
| Oyster Point Pharma, INC. | $91.33 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Genentech USA, INC. | $88.50 | 2023-2025 | Vabysmo |
| Shire North American Group INC | $85.49 | 2019 | |
| Astellas Pharma US INC | $84.58 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $78.80 | 2023-2025 | Miebo, Xiidra, Xipere |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $60.34 | 2019-2020 | |
| Amgen INC. | $53.60 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $45.80 | 2025 | Iluvien |
| Glaukos Corporation | $28.69 | 2024 | Idose |
| Biotissue Holdings INC. | $25.35 | 2019 | |
| Apellis Pharmaceuticals, INC. | $21.52 | 2025 | Syfovre |
| Sight Sciences, INC. | $18.60 | 2023 | Omni Surgical System |
| Alimera Sciences, INC. | $16.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Apter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.